Guannan Wang, PhD, Senior Research Investigator, discusses how they are
identifying the driver mutations and clinically actionable biomarkers in all common canine cancers, to arm
veterinary clinicians with better prognostic information, target therapeutic options, and markers to predict
treatment response, ultimately enabling precision medicine in canine oncology.
Enter Presenter 3 Header
Enter Presenter 3 Name
Enter Presenter 3 Title
Guannan Wang, PhD, Senior Research Investigator, discusses how they are
identifying the driver mutations and clinically actionable biomarkers in all common canine cancers, to arm
veterinary clinicians with better prognostic information, target therapeutic options, and markers to predict
treatment response, ultimately enabling precision medicine in canine oncology.
Enter Presenter 4 Header
Enter Presenter 4 Name
Enter Presenter 4 Title
Guannan Wang, PhD, Senior Research Investigator, discusses how they are
identifying the driver mutations and clinically actionable biomarkers in all common canine cancers, to arm
veterinary clinicians with better prognostic information, target therapeutic options, and markers to predict
treatment response, ultimately enabling precision medicine in canine oncology.
Enter Presenter 5 Header
Enter Presenter 5 Name
Enter Presenter 5 Title
Guannan Wang, PhD, Senior Research Investigator, discusses how they are
identifying the driver mutations and clinically actionable biomarkers in all common canine cancers, to arm
veterinary clinicians with better prognostic information, target therapeutic options, and markers to predict
treatment response, ultimately enabling precision medicine in canine oncology.
Enter Presenter 6 Header
Enter Presenter 6 Name
Enter Presenter 6 Title
Guannan Wang, PhD, Senior Research Investigator, discusses how they are
identifying the driver mutations and clinically actionable biomarkers in all common canine cancers, to arm
veterinary clinicians with better prognostic information, target therapeutic options, and markers to predict
treatment response, ultimately enabling precision medicine in canine oncology.
